Poland's Adamed buys 60% of Italy's Ecupharma in cross-border pharma push
What's the deal? Gruppo AdamedDealroom has a profile for this one. Try Dealroom →, a Polish pharmaceutical and biotechnology company, has acquired a 60% majority stake in Ecupharma S.r.l.Dealroom has a profile for this one. Try Dealroom →, an Italian drugmaker. The deal value was undisclosed.
Who's involved? Adamed, founded in 1986, carries a portfolio of nearly 900 products. Ecupharma is active in neurology, psychiatry, urology, and diabetology.
What's the endgame? The majority stake gives Adamed a foothold in the Italian market and adds Ecupharma's therapeutic specialisms to its lineup. It extends the Polish group's reach beyond its home base into Western Europe.
Who advised? Adamed was advised by ADVANT NctmDealroom has a profile for this one. Try Dealroom →, with partners Lorena Possagno and Jacopo Arnaboldi coordinating, and Francesco Mazzocchi handling Golden Power regulatory matters. The sellers were advised by LCA Studio LegaleDealroom has a profile for this one. Try Dealroom →, led by partner Marina Rosito.
The signal: The deal reflects continued cross-border consolidation in European pharma, as mid-sized players expand into new geographies and therapeutic niches through majority acquisitions rather than building from scratch.
Read more: leadersleague.com
Image credit: Generated with Gemini
